Eli Lilly's Retatrutide Demonstrates Superior Weight Loss and A1C Reduction Compared to Ozempic in Phase 3 Trial
Eli Lilly (LLY) has announced positive results from its Phase 3 clinical trial for retatrutide, a next-generation weight loss therapy. The study indicates that retatrutide achieved significantly higher levels of weight loss and more substantial reductions in A1C—a key diabetes biomarker—when compared to the highest approved dose of Novo Nordisk's (NVO) Ozempic. The results position retatrutide as a potential market leader in the highly competitive obesity and diabetes therapeutic sectors. By outperforming an established industry standard, Lilly strengthens its competitive moat against Novo Nordisk in the rapidly expanding GLP-1 receptor agonist market.
Topics: clinical trial results diabetes treatment weight loss drugs